Last reviewed · How we verify
Beclomethasone dipropionate BAI
Beclomethasone dipropionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.
Beclomethasone dipropionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone dipropionate BAI |
|---|---|
| Also known as | BDP, breath-actuated inhaler |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | Phase 3 |
Mechanism of action
As a synthetic corticosteroid, beclomethasone dipropionate enters cells and binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced recruitment and activation of immune cells. The dipropionate ester formulation enhances local tissue penetration and activity while minimizing systemic absorption.
Approved indications
- Asthma (maintenance and reliever therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia / hoarseness
- Tremor
- Headache
- Palpitations
Key clinical trials
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma (PHASE3)
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma (PHASE3)
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma (PHASE3)
- Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma (PHASE3)
- A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults (PHASE1)
- Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: